doi:10.47391/JPMA.10641Moaz, MuhammadImran, Muhammad WaleedNawaz, Sanwal SardarJournal of the Pakistan Medical Association
One of the ground-breaking developments was the identification of specific genetic mutations that drive breast cancer progression and predictive biomarkers, which can be used for targeted therapy. For example, the presence of Human Epidermal Growth Factor Receptor 2 (HER2) mutations led to advancements...
In the past 13 months, the FDA has granted accelerated approvals for 2 novel ADCs: fam-trastuzumab deruxtecan-nxki (Enhertu), for patients with unresectable or metastatic HER2-positive breast cancer who have received 2 or more prior anti–HER2- based regimens in the metastatic setting3; and...
Sequencing and analysis for this project were funded by the European Union’s Horizon 2020 Research and Innovation Program (BRIDGES: grants 634935 to A.G.-N., A.M.D., A.K., P.D. and D.F.E.), the PERSPECTIVE I&I project (funded by the Government of Canada through Genome Canada an...
The long-sought discovery of HER2 as an actionable and highly sensitive therapeutic target was a major breakthrough for the treatment of highly aggressive HER2-positive breast cancer, leading to approval of the first HER2-targeted drug — the monoclonal
The European Institute for Biomedical Imaging Research (EIBIR) in Vienna, Austria The SOLUS project is an initiative of the Photonics Public Private Partnership. This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant...
Figure 9: First-in-Class Products in the Breast Cancer Pipeline, Part 1 Figure 10: First-in-Class Products in the Breast Cancer Pipeline, Part 2 Figure 11: Signaling Network, Disease Causation and Innovation Alignment Analysis Figure 12: First-in-Class...
Implementing an innovation to improve coordination of care in breast cancer. Background: Janani Suraksha Yojana (JSY) is a maternal protection scheme that promotes institutional delivery by providing cash incentive to the mothers wh... NA Bickell,R Franco,A Moss,... - 《Journal of Clinical ...
This effect of RACK1 is associated with its ability to enhance β-catenin stability and activate the canonical WNT signaling pathway in breast cancer cells. We identified PSMD2, a key component of the proteasome, as a novel binding partner for RACK1 and β-catenin. Interestingly, although ...
Breast cancer is a heterogeneous disease, affecting over 3.5 million women worldwide, yet the functional role of cis-regulatory elements including super-enhancers in different breast cancer subtypes remains poorly characterized. Triple-negative breast ca